Taken together, the results validate STEAP2 as an ideal prostate tumor antigen displaying high, largely homogeneous expression throughout all stages of disease progression, as well as cell surface distal, normal tissue expression confined to the prostate. The gene discussed is STEAP2; the disease is neoplasm.